acalabrutinib造句

• Ibrutinib and acalabrutinib are other inhibitors that are being used or researched for similar treatments.
• These findings strongly suggest an improved safety profile of acalabrutinib with minimized adverse effects relative to ibrutinib.
• An additional clinical trial is currently in progress to directly compare the safety and efficacy performance of acalabrutinib to ibrutinib to better elucidate the differences in the therapeutic agents.
• In addition, in platelets treated with ibrutinib, thrombus formation was clearly inhibited while no impact to thrombus formation was identified relative to controls for those treated with acalabrutinib.
• Approximately 1, 000 patients have been treated with acalabrutinib in clinical trials so far, including more than 600 on acalabrutinib alone and almost 400 on additional therapies in combination with acalabrutinib.
• Approximately 1, 000 patients have been treated with acalabrutinib in clinical trials so far, including more than 600 on acalabrutinib alone and almost 400 on additional therapies in combination with acalabrutinib.
• Approximately 1, 000 patients have been treated with acalabrutinib in clinical trials so far, including more than 600 on acalabrutinib alone and almost 400 on additional therapies in combination with acalabrutinib.
• As was conducted in the development of ibrutinib, pre-clinical studies of acalabrutinib included " in vitro " and " in vivo " pharmacodynamic evaluation in a canine lymphoma model.
• Despite the appearance of a greater occurrence of transient headaches, the pre-clinical data suggests a preferred advantage of acalabrutinib over ibrutinib due to expected reduced adverse events of skin rash, severe diarrhea, and bleeding risk.
• While the primary indication is for CLL, as of late 2016, acalabrutinib is under evaluation for multiple indications in 20 + clinical trials ( alone and in combination with other interventions ) for various blood cancers, solid tumors, and rheumatoid arthritis.
• Relative to ibrutinib, acalabrutinib demonstrated higher selectivity and inhibition of the targeted activity of BTK, while having a much greater IC 50 or otherwise virtually no inhibition on the kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1.
• As of February 2016, acalabrutinib had received orphan designation in the United States for CLL only, and was similarly designated as an orphan medicinal product by the European Medicines Agency ( EMA ) Committee for Orphan Medicinal Products ( COMP ) for treatment of three indications-chronic lymphocytic leukemia ( CLL ) / small lymphocytic lymphoma ( SLL ), mantle cell lymphoma ( MCL ), and lymphoplasmacytic lymphoma ( Waldenstr鰉's macroglobulinaemia, MG ).